Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
Small-cell lung cancer (SCLC) is a fatal subtype of lung cancer characterized by high aggressiveness, poor prognosis, and limited treatment options. For the first time in more than three decades, it has been demonstrated that the addition of immunotherapy to chemotherapy improved the survival of pat...
Main Authors: | Shuang Zhang, Ying Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1142081/full |
Similar Items
-
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients
by: Martina Lorenzi, et al.
Published: (2024-01-01) -
Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting
by: Jacob Sands, et al.
Published: (2023-12-01) -
Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment
by: Li Liu, et al.
Published: (2023-07-01) -
Extensive Stage Small-Cell Lung Cancer with Cystic Brain Metastases: A Report of Two Cases
by: Cai F, et al.
Published: (2024-03-01) -
Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
by: Zhang C, et al.
Published: (2023-09-01)